Achillion Pharmaceuticals Inc. (ACHN) Stock Rating Reaffirmed by Jefferies Group
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN)‘s stock had its “hold” rating restated by stock analysts at Jefferies Group in a report issued on Monday.
Other research analysts have also issued reports about the stock. Leerink Swann reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, June 12th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 17th. Chardan Capital increased their price target on shares of Achillion Pharmaceuticals from $4.00 to $5.00 and gave the stock a “sell” rating in a research note on Friday, September 23rd. JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price objective for the company in a research note on Thursday, July 7th. Finally, FBR & Co started coverage on shares of Achillion Pharmaceuticals in a research note on Thursday, September 15th. They set an “outperform” rating and a $16.00 price objective for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $10.70.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 8.25 on Monday. The firm has a 50-day moving average of $8.44 and a 200-day moving average of $8.44. The stock has a market capitalization of $1.13 billion, a PE ratio of 168.37 and a beta of 2.21. Achillion Pharmaceuticals has a 1-year low of $5.57 and a 1-year high of $10.95.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the business earned ($0.25) earnings per share. Equities analysts expect that Achillion Pharmaceuticals will post ($0.61) EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of ACHN. BlackRock Fund Advisors increased its position in Achillion Pharmaceuticals by 2.3% in the first quarter. BlackRock Fund Advisors now owns 4,573,313 shares of the biopharmaceutical company’s stock worth $35,306,000 after buying an additional 102,179 shares during the last quarter. RTW Investments LLC increased its position in Achillion Pharmaceuticals by 31.1% in the first quarter. RTW Investments LLC now owns 2,558,859 shares of the biopharmaceutical company’s stock worth $19,754,000 after buying an additional 606,937 shares during the last quarter. Spark Investment Management LLC acquired a new position in Achillion Pharmaceuticals during the first quarter worth about $891,000. HBK Investments L P acquired a new position in Achillion Pharmaceuticals during the first quarter worth about $455,000. Finally, Legal & General Group Plc increased its position in Achillion Pharmaceuticals by 15.7% in the first quarter. Legal & General Group Plc now owns 18,010 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 2,443 shares during the last quarter. 79.43% of the stock is currently owned by institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.